ScholarIQanswers from OpenAlex & ORCID
Sean J. Barbour
ResearcherPublications, citations & collaboration network
Sean J. Barbour is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Sean J. Barbour have?
ScholarIQindexed works
Sean J. Barbour has 86 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Sean J. Barbour have?
ScholarIQcitation count
Sean J. Barbour has 4,461 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Sean J. Barbour?
ScholarIQh-index
Sean J. Barbour has an h-index of 33 in OpenAlex.
What is the i10-index of Sean J. Barbour?
ScholarIQi10-index
Sean J. Barbour has an i10-index of 54 in OpenAlex.
What is the OpenAlex record for Sean J. Barbour?
ScholarIQopenalex
The OpenAlex for Sean J. Barbour is on the source record.
What are the most-cited papers on Sean J. Barbour?
ScholarIQmost cited works
Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy
Fernando C. Fervenza, Gerald B. Appel, Sean J. Barbour, Brad H. Rovin, Richard Lafayette, Nabeel Aslam, Jonathan Ashley Jefferson, Patrick E. Gipson, Dana V. Rizk, John R. Sedor, James F. Simon, Ellen T. McCarthy, Paul Brenchley, Sanjeev Sethi, Carmen Ávila-Casado, Heather Beanlands, John C. Lieske, David Philibert, Tingting Li, Leslie F. Thomas, Dolly F. Green, Luis A. Juncos, Lada Beara‐Lasić, Samuel S. Blumenthal, Amy N. Sussman, Stephen B. Erickson, Michelle Hladunewich, Pietro A. Canetta, Lee A. Hebert, Nelson Leung, Jay Radhakrishnan, Heather N. Reich, Samir V. Parikh, Debbie S. Gipson, Dominic K. Lee, Bruno R. da Costa, Peter Jüni, Daniel Cattran
Evaluating a New International Risk-Prediction Tool in IgA Nephropathy
Sean J. Barbour, Rosanna Coppo, Hong Zhang, Zhi-Hong Liu, Yusuke Suzuki, Keiichi Matsuzaki, Ritsuko Katafuchi, Lee Er, Gabriela Espino-Hernández, S. Joseph Kim, Heather N. Reich, John Feehally, Daniel Cattran, International IgA Nephropathy Network
The MEST score provides earlier risk prediction in lgA nephropathy
Sean J. Barbour, Gabriela Espino-Hernández, Heather N. Reich, Rosanna Coppo, Ian S.D. Roberts, John Feehally, Andrew M. Herzenberg, Daniel C. Cattran, Nüket Bavbek, Terry Cook, S. Troyanov, Charles E. Alpers, Alfonso Amore, Jonathan Barratt, F. Berthoux, Stephen M. Bonsib, Jan A. Bruijn, Vivette D. D’Agati, Giuseppe D’Amico, Steven N. Emancipator, F. Emmal, Franco Ferrario, Fernando C. Fervenza, Sandrine Florquin, Agnes B. Fogo, Colin Geddes, Hermann-Josef Groene, Mark Haas, P. Hill, Ronald J. Hogg, Stephen I‐Hong Hsu, Tracy E. Hunley, Michelle Hladunewich, Caroline E. Jennette, Kensuke Joh, Bruce A. Julian, Takeshi Kawamura, F M Lai, Chi Bon Leung, L. Li, P. Li, Zhihong Liu, A. Massat, Bruce Mackinnon, Sergio Mezzano, Francesco Paolo Schena, Yasuhiko Tomino, Patrick D. Walker, H. Wang, Jan J. Weening, Nori Yoshikawa, H. Zhang, Rosanna Coppo, S. Troyanov, Daniel C. Cattran, H. Terence Cook, John Feehally, Ian S.D. Roberts, Vladimı́r Tesař, Dita Maixnerová, Sigrid Lundberg, Loreto Gesualdo, Francesco Emma, Laura Fuiano, G. Beltrame, Cristiana Rollino, Rc, Alfonso Amore, Roberta Camilla, Licia Peruzzi, Manuel Praga, Sandro Feriozzi, Rosaria Polci, Giuseppe Segoloni, Loredana Colla, Antonello Pani, Andrea Angioi, Lisa Adele Piras, JF JF, Giovanni Cancarini, S. Ravera, Magdalena Durlik, Elisabetta Moggia, José Ballarín, S. Di Giulio, Francesco Pugliese, I. Serriello, Y. Caliskan, Mehmet Şükrü Sever, İşın Kiliçaslan, Francesco Locatelli, Lucia Del Vecchio, Jack F.M. Wetzels, Harm Peters, U. Berg, Fernanda Carvalho, A.C. da Costa Ferreira, M. Maggio, Andrzej Więcek, Mai Ots-Rosenberg
Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial
David Z.I. Cherney, Claire C. J. Dekkers, Sean J. Barbour, Daniel C. Cattran, Abdul Halim Abdul Gafor, Peter J. Greasley, Gozewijn D. Laverman, Soo Kun Lim, Gian Luca Di Tanna, Heather N. Reich, Marc Vervloet, Muh Geot Wong, Ron T. Gansevoort, Hiddo J.L. Heerspink
Disease-specific risk of venous thromboembolic events is increased in idiopathic glomerulonephritis
Sean J. Barbour, Allen Greenwald, Ognjenka Djurdjev, Adeera Levin, Michelle Hladunewich, Patrick H. Nachman, Susan L. Hogan, Daniel C. Cattran, Heather N. Reich